Thrivent Financial for Lutherans’s NovoCure NVCR Stock Holding History

Thrivent Financial for Lutherans’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-26,003	Closed	-$775K	–	2490
2024 Q4	$775K	Sell	26,003 -10,492	-29%	-$222K	﹤0.01%	2037
2024 Q3	$570K	Hold	36,495	–	–	﹤0.01%	2190
2024 Q2	$626K	Buy	+36,495	New	+$642K	﹤0.01%	2128
2019 Q4	–	Sell	-47,318	Closed	-$3.54M	–	2249
2019 Q3	$3.54M	Sell	47,318 -41,558	-47%	-$3.32M	0.01%	766
2019 Q2	$5.62M	Buy	88,876 +1,142	+1%	+$57.9K	0.02%	667
2019 Q1	$4.23M	Sell	87,734 -52,939	-38%	-$2.55M	0.01%	719
2018 Q4	$4.71M	Buy	140,673 +21,131	+18%	+$773K	0.02%	626
2018 Q3	$6.26M	Sell	119,542 -14,412	-11%	-$574K	0.02%	607
2018 Q2	$4.19M	Buy	+133,954	New	+$3.73M	0.01%	689

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Thrivent Financial for Lutherans's NVCR Position: Q1 2025 in Review

Thrivent Financial for Lutherans sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 26,003 shares — an estimated $775K sold.

Thrivent Financial for Lutherans first reported a position in NVCR in Q2 2018 and held it in 9 quarters. The position peaked at $6.26M in Q3 2018. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

Thrivent Financial for Lutherans reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
Thrivent Financial for Lutherans sold 26,003 NovoCure shares in Q1 2025, an estimated $775K.
Thrivent Financial for Lutherans first reported a position in NovoCure in Q2 2018 and held it in 9 quarters.
Thrivent Financial for Lutherans's NovoCure position peaked at $6.26M in Q3 2018.
227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2025, filed 13 May 2025.